Vagelos P Roy
Regeneron Pharmaceuticals, Inc, USA.
Cleve Clin J Med. 2007 Mar;74 Suppl 2:S12-3; discussion 16-22. doi: 10.3949/ccjm.74.suppl_2.s12.
Every phase of the development of biopharmaceuticals and medical devices has the potential for conflict of interest, but adherence to established rules and practices throughout product development can eliminate the possibility of conflicts. Adherence to good practices should continue through the postmarketing period, with swift reporting and vigorous investigation of any safety concerns. Although some academic medical centers are restricting interactions between their faculty and industry to prevent possible conflicts in physician education about new products, industry and academia should look for new ways to come together in mutually agreed forums that focus on educating clinicians about new products in an efficient, transparent way.
